Abstract
During the last years, mass spectrometry has revolutionised protein biochemistry and has advanced to a superior tool for the identification and detailed analysis of peptides and proteins. The high throughput allowed by some mass spectrometry platforms has enabled the important step from analysis of individual proteins to proteomics. Recently, an additional field of mass spectrometry applications has emerged - namely screening and diagnostic research. In contrast to protein identification, screening applications have to detect analyte molecules of defined molecular weights which can be calculated beforehand, for example by means of chemical structures. Here, the accuracy and sensitivity of mass spectrometry has to be combined with the requirements of high-throughput analyses, in particular speed and automation. These criteria are especially fulfilled by state of the art matrix-assisted laser desorption/ionisation time-offlight mass spectrometry (MALDI-TOF MS) instruments. The first high throughput screening (HTS) application proved to be genotyping of single nucleotide polymorphisms. The same principle was later applied for several quality control issues, for example for oligonucleotides, peptide or compound libraries. This development has culminated in the screening and profiling of complex biomarker patterns in clinical proteomics to detect a molecular fingerprint for specific diseases in biological samples. Thus, mass spectrometry based methods are expected to enable a very early diagnosis of diseases with minimally invasive methods of investigation. This type of high end screening application has the potential to revolutionise the early diagnosis of many diseases. Here, we give an overview of the application of mass spectrometry in the fields of screening and diagnostic research.
Keywords: serum profiling, biomarkers, snp genotyping, quality control, screening, diagnosis, maldi-tof
Current Pharmaceutical Design
Title: Application of MALDI-TOF Mass Spectrometry in Screening and Diagnostic Research
Volume: 11 Issue: 20
Author(s): W. Pusch and M. Kostrzewa
Affiliation:
Keywords: serum profiling, biomarkers, snp genotyping, quality control, screening, diagnosis, maldi-tof
Abstract: During the last years, mass spectrometry has revolutionised protein biochemistry and has advanced to a superior tool for the identification and detailed analysis of peptides and proteins. The high throughput allowed by some mass spectrometry platforms has enabled the important step from analysis of individual proteins to proteomics. Recently, an additional field of mass spectrometry applications has emerged - namely screening and diagnostic research. In contrast to protein identification, screening applications have to detect analyte molecules of defined molecular weights which can be calculated beforehand, for example by means of chemical structures. Here, the accuracy and sensitivity of mass spectrometry has to be combined with the requirements of high-throughput analyses, in particular speed and automation. These criteria are especially fulfilled by state of the art matrix-assisted laser desorption/ionisation time-offlight mass spectrometry (MALDI-TOF MS) instruments. The first high throughput screening (HTS) application proved to be genotyping of single nucleotide polymorphisms. The same principle was later applied for several quality control issues, for example for oligonucleotides, peptide or compound libraries. This development has culminated in the screening and profiling of complex biomarker patterns in clinical proteomics to detect a molecular fingerprint for specific diseases in biological samples. Thus, mass spectrometry based methods are expected to enable a very early diagnosis of diseases with minimally invasive methods of investigation. This type of high end screening application has the potential to revolutionise the early diagnosis of many diseases. Here, we give an overview of the application of mass spectrometry in the fields of screening and diagnostic research.
Export Options
About this article
Cite this article as:
Pusch W. and Kostrzewa M., Application of MALDI-TOF Mass Spectrometry in Screening and Diagnostic Research, Current Pharmaceutical Design 2005; 11 (20) . https://dx.doi.org/10.2174/1381612054546932
DOI https://dx.doi.org/10.2174/1381612054546932 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characteristics and Risk Factors Associated with Stroke Subtypes among Adult Patients Admitted to the Stroke Unit of Jimma University Medical Center: A Retrospective Cross-sectional Study
Current Hypertension Reviews Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Molecular Targeted Therapy of Gastrointestinal Stromal Tumors
Current Cancer Drug Targets Safety and Efficacy of Intra-arterial Tirofiban Injection During Mechanical Thrombectomy for Large Artery Occlusion
Current Neurovascular Research Development of Enzyme-Linked Immunosorbent Assay System for PEDF and its Clinical Utility
Current Molecular Medicine Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
Current Pharmaceutical Design Hypoperfusion of the Aortic Wall Secondary to Degeneration of Adventitial Vasa Vasorum Causes Abdominal Aortic Aneurysms
Current Drug Targets Antioxidants in the Treatment of Diabetes
Current Diabetes Reviews Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?
Current Drug Safety PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design Can Probiotics Cure Inflammatory Bowel Diseases?
Current Pharmaceutical Design Design of a Genetically Modified Soybean Protein Preventing Hypertension Based on an Anti-Hypertensive Peptide Derived from Ovalbumin
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association
Current Pharmaceutical Design Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets The Economics of Pharmacogenomics
Current Pharmacogenomics Amniotic Fluid Embolism: Review
Current Pharmaceutical Biotechnology Comparative Evaluation of Conventional and Novel Extracts of Stem Bark of Terminalia arjuna for Antihypertensive Activity in BSO Induced Oxidative Stress based Rat Model
Current Pharmaceutical Biotechnology Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents